Peregrine Pharmaceuticals Provides Update on Planned Expansion of Bavituximab …

Peregrine Pharmaceuticals Provides Update on Planned Expansion of Bavituximab …

In the first quarter of 2016, Peregrine plans to initiate two new Phase II clinical trials in breast and lung cancer in combination with current standard of care treatments including both chemotherapy and immuno-oncology agents. In addition, the

(Visited 1 times, 1 visits today)
1
Like
Save

Comments

Comments are disabled for this post.